• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Quotient Limited (Amendment)

    2/21/23 5:02:33 PM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QTNT alert in real time by email
    SC 13D/A 1 d449336dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Amendment #1

    Under the Securities Exchange Act of 1934

     

     

    QUOTIENT LIMITED

    (Name of Issuer)

    Ordinary Shares, nil par value

    (Title of Class of Securities)

    G73268149

    (CUSIP Number)

    Columbia Management Investment Advisers, LLC

    Attn: Matthew Rich

    290 Congress Street

    Boston, MA 02210

    Tel: (617) 385-9572

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    February 16, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☒.

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7(b) for other parties to whom copies are to be sent.

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No.        G73268149    SCHEDULE 13D    Page 2

     

      1    

      NAMES OF REPORTING PERSONS

    Ameriprise Financial, Inc.

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    IRS No. 13-3180631

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (See Instructions)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0

         8  

      SHARED VOTING POWER

     

      94,755(1)

         9  

      SOLE DISPOSITIVE POWER

     

      0

       10  

      SHARED DISPOSITIVE POWER

     

      94,755(1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      94,755(1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ☐

     

      Not Applicable

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.45%

    14  

      TYPE OF REPORTING PERSON (See Instructions)

     

      HC

     

    (1)

    Includes (i) 85,842 ordinary shares, nil par value (the “Ordinary Shares”) of Quotient Limited (the “Issuer”) and (ii) 8,913 Ordinary Shares issuable upon the exercise of the currently exercisable warrants with an exercise price of $30.00 per Ordinary Share (the “Warrants”).


    CUSIP No.        G73268149

       SCHEDULE 13D    Page 3

     

      1    

      NAMES OF REPORTING PERSONS

    Columbia Management

    Investment Advisers, LLC

     

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    IRS No.41-1533211

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (See Instructions)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Minnesota

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0

         8  

      SHARED VOTING POWER

     

      94,755(1)

         9  

      SOLE DISPOSITIVE POWER

     

      0

       10  

      SHARED DISPOSITIVE POWER

     

      94,755(1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      94,755(1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ☐

     

      Not Applicable

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0.45%

    14  

      TYPE OF REPORTING PERSON (See Instructions)

     

      IA

     

    (1)

    Includes (i) 85,842 ordinary shares, nil par value (the “Ordinary Shares”) of Quotient Limited (the “Issuer”) and (ii) 8,913 Ordinary Shares issuable upon the exercise of the currently exercisable warrants with an exercise price of $30.00 per Ordinary Share (the “Warrants”).


          Page 4

     

    Explanatory

    Note

    This Amendment No. 1 (the “Amendment”) amends and supplements the Schedule 13D filed by the Reporting Persons on December 15, 2022 (the “Original Schedule 13D” and, as amended and supplemented by this Amendment, the “Schedule 13D”), with respect to the Ordinary Shares.

    Except as specifically provided herein, the Amendment does not modify any of the information previously reported on the Original Schedule 13D. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original Schedule 13D.

     

    Item 4.

    Purpose of Transaction

    Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows:

    As previously disclosed, on December 5, 2022, the Reporting Persons entered into a transaction support agreement with the Issuer and the other Consenting Noteholders (the “Original TSA”). The Transaction Support Agreement was amended and restated on January 9, 2023 (the “A&R TSA”) to update and modify certain steps effectuating the transactions pursuant to which the Issuer will undergo a comprehensive restructuring of its balance sheet (collectively, the “Transactions”) remove references to the potential creditor schemes of arrangement in England, enhance the diligence available for the benefit of the consenting noteholders, provide for automatic termination (rather than termination only after receipt of written notice) upon certain events, and reduce the threshold of approval necessary to extend certain milestones set forth in the A&R TSA. The A&R TSA is otherwise substantially the same as the Original TSA.

    On January 10, 2023, in accordance with the A&R TSA, the Issuer filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”). On February 15, 2023 the Bankruptcy Court confirmed the Issuer’s plan of reorganization (the “Bankruptcy Plan”) and on February 16, 2023, and in accordance with the terms of the Bankruptcy Plan, the Issuer, Quotient Holdings Newco, LP (“Newco”), Quotient Holdings Finance Company Limited (“Finance Co”), Quotient Holdings GP, LLC, a Delaware limited liability company and the general partner of Newco (the “GP”), Quotient Holdings Merger Company Limited (“Merger Co”), each direct and indirect subsidiary of the Issuer and the Consenting Noteholders entered into a Master Transaction Agreement (the “Master Transaction Agreement”), and the Issuer, Newco and Finance Co entered into a Business and Asset Transfer Agreement (the “BTA”), and the Issuer effected the transactions contemplated by the Master Transaction Agreement and the BTA, emerged from bankruptcy protection, and the Bankruptcy Plan went effective.

    Pursuant to the A&R TSA, Bankruptcy Plan, the Master Transaction Agreement and the BTA, on February 16, 2023, a series of transactions occurred which resulted in the Convertible Notes and Senior Secured Notes being extinguished, the Issuer issuing 13,020,000 Ordinary Shares to Finance Co and 4,000,000 Ordinary Shares to Merger Co, resulting in Newco indirectly owning approximately 81% of the outstanding Common Shares of the Issuer, and all of the subsidiaries of the Issuer becoming indirect wholly-owned subsidiaries of Newco. The limited partnership interests in Newco are held by certain of the Consenting Noteholders. The A&R TSA, Bankruptcy Plan, and Master Transaction Agreement further provide that as soon as practicable following the effective date, the Issuer, Finance Co. and Merger Co will enter into a


          Page 5

     

    merger agreement that will result in the Issuer becoming a wholly-owned indirect subsidiary of Newco (the “Merger”). The Master Transaction Agreement provides that the parties thereto will cooperate as reasonably necessary or desirable to consummate the Merger as soon as possible. Upon completion of the Merger, the Issuer is expected to terminate the registration of its equity securities under the Securities Exchange Act of 1934, as amended.

    The Reporting Persons does not have the ability, directly or indirectly, to direct the voting or disposition of Ordinary Shares held by Newco.

    Following the consummation of the transactions that occurred on February 16, 2023, any “group” that may be deemed to have existed between the Reporting Persons and other Consenting Noteholders has been terminated.

    The foregoing descriptions of the A&R TSA, the Master Transaction Agreement and the BTA are summaries only, do not purport to be complete and are qualified in their entirety by reference to the full text of the A&R TSA (including the exhibits thereto), the Master Transaction Agreement and the BTA, copies of which are attached hereto as Exhibits 99.3, 99.4 and 99.5, respectively, and incorporated herein by reference.

     

    Item 5.

    Interest in Securities of the Issuer

    Item 5 of the Original Schedule 13D is hereby amended and restated as follows:

    The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Statement is incorporated by reference in its entirety into this Item 5.

    (a), (b), The percentage of Ordinary Shares beneficially owned by the Reporting Persons is based on (i) 4,035,013 Ordinary Shares reported outstanding as of February 2, 2023 in the Issuer’s Form 10-Q for the quarterly period ended December 31, 2022, plus (ii) 17,020,000 Ordinary Shares issued on February 16, 2023, as described in Item 4.

    (c) Other than as described in Item 4 and in Schedule B annexed hereto, the Reporting Persons have not effected transactions in the Ordinary Shares during the past sixty days.

    (d) No person other than the Reporting Persons are known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Ordinary Shares held by the Reporting Persons.

    (e) February 16, 2023.

     

    Item 6.

    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

    Item 6 of the Original Schedule 13D is hereby amended and supplemented as follows:

    The information set forth in Items 4 and 5 is incorporated herein by reference.

    Other than as described in this Item 6 and Items 4 and 5, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 hereof and between such persons and any person with respect to any securities of the Issuer, including but not limited


          Page 6

     

    to transfer or voting of any other securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies, including any securities pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities other than standard default and similar provisions contained in loan agreements.

     

    Item 7.

    Material to Be Filed as Exhibits

    Item 7 of the Original Schedule 13D is hereby amended and supplemented as follows:

     

    Exhibit 99.1    Joint filing Agreement
    Exhibit 99.2    Transaction Support Agreement, as amended and restated (incorporated by reference to Exhibit 10.1 attached to the Issuer’s Current Report on Form 8-K filed with the SEC on January 10, 2023).
    Exhibit 99.3    Master Transaction Agreement (incorporated by reference to Exhibit 99.5 to the Schedule 13D/A filed by Whitebox Advisors LLC, Whitebox General Partner LLC, Whitebox Relative Value Partners, LP, Whitebox Multi-Strategy Partners, LP, Pandora Select Partners L.P., and Whitebox GT Fund, LP, with respect to the securities of Quotient Limited on February 21, 2023).
    Exhibit 99.4    Business and Asset Transfer Agreement (incorporated by reference to Exhibit 99.6 to the Schedule 13D/A filed by Whitebox Advisors LLC, Whitebox General Partner LLC, Whitebox Relative Value Partners, LP, Whitebox Multi-Strategy Partners, LP, Pandora Select Partners L.P., and Whitebox GT Fund, LP, with respect to the securities of Quotient Limited on February 21, 2023).


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 21, 2023

     

    Ameriprise Financial, Inc.
    By:   /s/ Michael G. Clarke
    Name:   Michael G. Clarke
    Title:   Senior Vice President, Head of Global Operations & Investor Services
    Columbia Management Investment Advisers, LLC
    By:   /s/ Michael G. Clarke
    Name:   Michael G. Clarke
    Title:   Senior Vice President, Head of Global Operations & Investor Services


    SCHEDULE B

    TRANSACTIONS IN THE SHARES DURING THE PAST 60 DAYS

     

    FOR THE

    ACCOUNT OF

       SHARES OF COMMON
    PURCHASED/(SOLD)
       

    PRICE PER

    SHARE ($U.S.)

        

    DATE OF

    PURCHASE/SALE

     

    Client 1

         (665.00 )      0.2709        12/19/2022  

    Client 2

         (5.00 )      0.2200        12/23/2022  

    Client 3

         (3.00 )      0.4400        12/27/2022  

    Client 4

         (155.00 )      0.3300        01/04/2023  

    Client 5

         31.00       0.1350        01/13/2023  

    Client 1

         (644.00 )      0.1100        01/18/2023  

    Client 6

         (339.00 )      0.0680        01/31/2023  

    Client 7

         (267.00 )      0.0660        02/01/2023  

     

    Get the next $QTNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QTNT

    DatePrice TargetRatingAnalyst
    12/3/2021$4.00 → $3.50Neutral
    Goldman Sachs
    8/6/2021$5.00 → $4.50Neutral
    Goldman Sachs
    More analyst ratings

    $QTNT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Quotient Limited

      15-12G - Quotient Ltd (0001596946) (Filer)

      6/30/23 7:56:39 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Quotient Limited

      EFFECT - Quotient Ltd (0001596946) (Filer)

      6/30/23 12:15:07 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Quotient Limited

      EFFECT - Quotient Ltd (0001596946) (Filer)

      6/30/23 12:15:20 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care